Open access
Jul 2026
Preclinical Safety Evaluation of a Replication-Defective Canine Adenovirus Type 2 Vector-Based SARS-CoV-2 Vaccine Candidate in Murine Models
It is demonstrated that the CAV-2 vector exhibits a favourable safety profile in murine models when used as a vaccine delivery platform, supporting its translational potential as an alternative adenoviral vector-based vaccine platform.
Denis Omara, Christian Ndekezi, S. Mugaba et al.
· Vaccines · 0 citations